Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
MELBOURNE, Australia and HONG KONG, Nov. 02, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand Pharma’) for Telix’s portfolio of Molecularly-Targeted Radiation (‘MTR’) products.
Telix has appointed China Grand Pharma as its exclusive partner for the Greater China market (‘Territory’)1 and grants China Grand Pharma exclusive development and commercialisation rights to Telix’s portfolio of prostate, renal and brain (glioblastoma) cancer imaging and therapeutic MTR products in the Territory.
Leveraging off China Grand Pharma’s capabilities and infrastructure in China, Telix will enter a significant oncology market, and by partnering with Telix, China Grand Pharma will build on its pipeline of innovative products for Greater China, as well as its strategy in Nuclear Medicine.
The material terms of the partnership include:
US$25M (~AU$35M) up-front non-refundable prepayment to Telix, to be credited against future regulatory and commercial milestone payments.
Up to US$225M (~AU$315M) in regulatory and commercial milestone payments to Telix, across Telix’s existing therapeutic products portfolio.
Program-related investment estimated at up to US$65M (~AU$90M) for clinical costs associated with the development of the therapeutic products in the Territory, to align with Telix’s global clinical development programs.
Royalties on therapeutic product sales in the Territory, in addition to milestone payments.
Exclusive commercial partnership (sales, marketing, distribution) for Telix’s core imaging product portfolio:
TLX250-CDx (89Zr-Girentuximab) for renal cancer, and;
TLX591-CDx (68Ga-PSMA), TLX599-CDx (99Tc-PSMA) for prostate cancer.
Strategic Equity Investment
Additionally, China Grand Pharma will make a simultaneous one-time strategic equity investment of US$25M (~AU$35M) in Telix. The investment is in the form of a private placement to China Grand Pharma of 20,947,181 fully paid ordinary Telix shares representing a post-issue holding by China Grand Pharma of 7.62%. Shares will be issued at a price of AU$1.69, based on the 10-day volume-weighted average price (‘VWAP’) for Telix shares up to and including 28th October 2020. Shares will be issued no later than November 06 2020, following receipt of the placement proceeds. Shares issued to China Grand Pharma are subject to a holding lock and will not be able to be traded for a period of 12 months from the date of issue. In addition, China Grand Pharma is subject to a standstill provision and is unable to trade in Telix shares for a period of 12 months.
Telix Pharmaceuticals CEO, Dr. Chris Behrenbruch stated, “Telix’s mission is to be a leading global oncology company and China is an important future market for our products. We are pleased to be working with China Grand Pharma to deliver our diagnostic imaging and therapeutic products to cancer patients in China. Considering the successful acquisition of Sirtex Medical Limited with joint venture private equity partner CDH Genetech Limited2 and subsequent approval of a New Drug Application filing for SIR-Spheres® by the National Medical Products Administration (‘NMPA’) of the
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research
Novocure (NASDAQ: NVCR) today announced it has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’s Tumor Treating Fields are electric fields that disrupt cancer cell division.
“It is our goal to establish NYU as a center for Tumor Treating Fields research and development based on the academic interests of the Department of Radiation Oncology and its collaborators,” said Dr. Erik Sulman, co-director of the Brain and Spine Tumor Center at NYU Langone’s Perlmutter Cancer Center. “This partnership will help bring us closer to our goal through the development of preclinical and clinical shared platforms, and facilitate rapid clinical trial development.”
Research to be conducted is designed to further the understanding of the interaction between Tumor Treating Fields and radiation therapy, to study Tumor Treating Fields in combination with various pharmacological agents, and to identify new indications for use. This translational research is intended to deepen the understanding of Tumor Treating Fields’ effects on cancer and to fuel development of new treatment strategies.
“We are excited to partner with a leading U.S. academic institution and look forward to working with NYU’s top researchers,” said William Doyle, Novocure’s Executive Chairman. “We believe that collaborations with leading academic research centers signify growing interest in Tumor Treating Fields across the scientific community and advance our mission to extend survival in some of the most aggressive forms of cancers.”
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields therapy uses electric fields to disrupt cancer cell division. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005211/en/
VeChain, Renji Hospital and DNV GL Held Strategic Partnership Signing Ceremony To Launch World’s First Blockchain Intelligent Tumor Treatment Center
SHANGHAI, Oct. 27, 2020 /PRNewswire/ — In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world’s first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020. The Intelligent Tumor Treatment Center is a transparent, efficient, and traceable medical management solution powered by VeChain ToolChainTM.
As strategic partners of this new initiative, VeChain and DNV GL will jointly support the hospital in the quest to improve global public health through state-of-the-art blockchain technology and professional advisory.
VeChain ToolChainTM Powers The World’s First Intelligent Tumor Treatment Center
The Intelligent Tumor Treatment Center combines the advantages of VeChain blockchain technology with DNV GL’s professional services. It enables full patient ownership of personal medical records, allowing patients to take control of the authorization and medical records data management. Research institutions inside and outside the hospital can use authorized data to improve the efficiency of clinical research, and regulatory agencies can use authorized data to conduct business compliance checks on medical institutions and establish a credit evaluation system.
Zhang Jidong, Vice President of Renji Hospital, said, “The launch of the Intelligent Tumor Treatment Centre intends to enhance high-quality integrated development of Renji Hospital. Moving forward, Renji intends to boost our healthcare facilities with more blockchain-powered use cases and projects, which will be gradually disclosed together with our partners when the time is right.”
George Kang, Senior Vice President of DNV GL Group, said, “Through independent and objective medical evaluation methods, DNV GL intends to provide more services for Renji Hospital to improve its service quality and medical experience, moving to a new stage of higher standards, higher requirements and higher quality.”
Sunny Lu, co-founder and CEO of VeChain, said, “As digital transformation accelerates in the healthcare sector, VeChain will continue to demonstrate its advantages and flexibility as a superior blockchain platform that is suitable for all types of use cases and industries. We are very proud and excited to be contributing to the public health industry by providing the technology for Renji Hospital’s Intelligent Tumor Treatment Centre.”
VeChain Facilitating Digital Transformation To Improve Public Health
In line with the Chinese Government’s 14th Five-Year (2021-2025) Plan for Economic and Social Development, the National Health Commission formulated an official guideline and re-emphasized blockchain technology as an essential innovation and integration of the medical and health industry. VeChain is committed to solving the pain points of digital medical reform through blockchain technology and balancing personal privacy and public interests.
By using the self-developed one-stop data BaaS platform VeChain ToolChainTM , we have many proven cases in the medical sector, including a blockchain powered Clinical Trial Traceability Platform for Bayer China, and a blockchain-enabled medical data management platform named The E-NewHealthLife
Contakt World Enters 3-Year Strategic Collaboration with Satcher Health Leadership Institute at Morehouse School of Medicine
Partnership to Improve Health Equity, Reduce Health Disparities, and Improve Community Health Amid COVID-19 Pandemic
OCEANSIDE, CA / ACCESSWIRE / October 22, 2020 / Contakt LLC, subsidiary of Contakt World Technologies Corp. (“Contakt World”), a technology company modernizing the contact tracing process, today announced a strategic partnership with the Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine to provide COVID-19 resources and the Contakt World Platform for digital contact tracing to support communities hardest hit by the pandemic. Over three years, Contakt will assist SHLI and local, state, and national health agency partners to identify, monitor and support marginalized populations who are at heightened risk of exposure and complications from coronavirus. The program is expected to reach all fifty United States and territories, as well as tribal nations disproportionately impacted by the COVID-19 pandemic.
SHLI is a leading academic institute within Morehouse School of Medicine that prioritizes research, training, and leadership development programs to eliminate inequities that prevent individuals from achieving optimal health. SHLI is leading several national projects to mitigate the impact of COVID-19 on vulnerable and underserved communities, including the the National Infrastructure for Mitigating the Impact of COVID-19 funded by the U.S. Department of Health and Human Services (HHS), and the Health Equity Tracker project with Google.org, CDC Foundation, and Gilead Sciences (NASDAQ: GILD). Both projects aim to understand the root cause of the disproportionate spread of COVID-19 and other co-morbidities in minority communities and provide accessible health solutions. As part of the 3-year initial term between Contakt World and SHLI – Contakt World intends to obtain United States entitlements to use the Google-Apple Exposure Notification System (“GAEN”), while adding functionality across an array of tools for consumers, health agencies, and businesses to improve health agency reach to marginalized populations who may not have access to the latest smartphones using GAEN.
“We are honored to partner with SHLI on this project to improve the overall health of all communities and provide the right tools and resources to communities fighting the COVID-19 pandemic,” said Justin Beck, Chief Executive Officer of Contakt World. “Any system designed for truly scaled digital contact tracing must be deliberately accessible and reach people where they are. We look forward to working with SHLI to ensure that no person is denied critical health information due to digital divides, language barriers or other limitations of trust or technology.”
Contakt World will enable any community working with SHLI with technologies to support their efforts to serve high risk areas. The Contakt World Platform will initially be available through the SHLI collaboration in Albany, GA., South Florida, New Orleans, LA., Moore County, TX., Alaska, Navajo Nation with plans to expand to all 50 states and territories within the next three years or earlier by request.
“COVID-19 has exposed and exacerbated health inequities that have existed long before the pandemic started earlier this year,” said Daniel E. Dawes, Director of the Satcher Health Leadership Institute at Morehouse School of Medicine and author of The Political
Philips and Marienhospital Stuttgart sign 10-year strategic partnership to improve patient care and efficiency
October 21, 2020
Long-term agreement guarantees access to state-of-the-art solutions, controls costs, and ensures security of future investment
Fully-integrated approach deploying Philips’ digital healthcare solutions across multiple departments to enhance the experience of Marienhospital Stuttgart’s patient and staff
Amsterdam, the Netherlands and Stuttgart, Germany – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Marienhospital Stuttgart (Germany) today signed a 10-year strategic partnership agreement to expand world-class medicine at the hospital and provide integrated patient care. The project will include renewal and ongoing development of the hospital’s diagnostic imaging equipment and associated IT systems, digitization of its pathology department, and enhancement of the hospital’s emergency medicine capabilities.
Rather than treating each of these improvement areas as a separate exercise, Philips and Marienhospital Stuttgart will integrate them into connected patient care and optimized efficiency solutions. This will involve analysis of the hospital’s current treatment structures and pathways to enhance the overall quality of the hospital’s structures, processes and results, while also identifying potential cost savings. By jointly developing needs-based technology solutions, Marienhospital Stuttgart will be able to better plan its costs and ensure investment security in all areas.
“Due to the long-term nature of our partnership with Philips, our hospital will not only actively participate in future technological advances in healthcare, but also become a leader,” said Markus Mord, Managing Director of Marienhospital Stuttgart. “It will enable us to offer our patients diagnostic and therapeutic procedures that consistently meet the latest standards. We live medicine and always focus on the well-being of our patients.”
“As a solution provider, we specialize in partnering with our customers to provide integrated care concepts that enhance treatment pathways for their patients,” said Peter Vullinghs, Managing Director Philips DACH. “With new, highly innovative approaches, we will help to enhance the quality of medical care for the benefit of the patient across the board. We look forward to many years of mutual cooperation with Marienhospital Stuttgart.”
Reliable diagnosis through digital pathology
A core element of the collaboration is redesign of the hospital’s pathology department workflow, replacing conventional microscopes and glass slides with Philips’ high-performance digital pathology slide scanners and computer workstations. This will allow slide images to be managed, displayed, analyzed and discussed with clinical colleagues – for example, during tumor boards for the diagnosis and treatment of cancers. The ability to share slide images will also enable virtual consultations with experts from other hospitals. Competence networks like this combine the experience of doctors working in the clinic with the knowledge of their research colleagues, speeding up right-first-time diagnosis and the initiation of therapy.
Radiology for current and future needs
Reflecting the holistic nature of the partnership model, Philips will also help to analyze and redefine Marienhospital Stuttgart’s radiology procedures, processes and IT systems, as well as coordinating equipment renewal and expansion. Under the terms of the agreement, Philips will be responsible for the procurement, installation, maintenance (including updates and upgrades) and servicing of all large radiology equipment, with